Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotic Recipe For High Prices: Outcomes Data, Targeted Use

Executive Summary

Drug developers must show value, such as lower death rates, to justify high prices for antibiotics to treat drug resistant organisms, payers note during conference on the Limited Population Antibacterial Drug approval pathway.

You may also be interested in...



Antibiotic Incentive Legislation: Can Reimbursement Horn In?

There are two antibiotic incentive bills vying for attention in Congress. One is a follow-on to the popular GAIN Act; the other takes a new path – creating generous reimbursement formulas to help the next wave of anti-infectives find a successful niche in hospital market.

Antibiotics For Drug-Resistant Infections Hope To Skip Phase III Trials

PhRMA working group lays out proposal to allow approval of antibiotics for infections constituting an unmet medical need based on open-label studies and observational data.

With GAIN In Place, Antibiotic Improvements Depend On FDA Implementation

FDA and industry are turning their attention to implementation of the Generating Antibiotic Incentives Now provisions of PDUFA V, which include an additional five years of marketing exclusivity for certain products and new guidance aimed at streamlining the drug development process.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel